drugset / Trial / NCT01853644
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 2
Completed
31 enrolled
Northwestern University
National Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well tivozanib works in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Tivozanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2013-06-06
- Primary completion
- 2018-10-02
- Completion
- 2021-05-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivozanib | Small molecule | 1.5 mg | Oral |